ARA-290 Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is ARA-290?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Small fiber neuropathy, neuropathic pain, diabetic neuropathy, neuroinflammation, cardiac aging, tissue protection
• First Developed: Early 2000s at the Feinstein Institutes for Medical Research by Dr. Michael Brines and Dr. Anthony Cerami
• Molecular Weight: 1,257.3 g/mol
• Research Status: Multiple completed Phase 2 human trials; no Phase 3 trials completed; no therapeutic approval from any regulatory authority
• Key Mechanisms: Innate Repair Receptor (IRR) activation, NF-kB suppression, TRPV1 channel inhibition, microglial suppression
• Published Studies: Multiple Phase 2 randomized controlled trials; extensive preclinical literature across neurological, cardiovascular, metabolic, and autoimmune models
• Clinical Trial Status: Phase 2 complete for sarcoidosis-associated small fiber neuropathy and type 2 diabetic neuropathy; no Phase 3 trials initiated
• Regulatory Classification: FDA Orphan Drug Product designation for neuropathic pain in sarcoidosis; research use only; not approved for human therapeutic application

What is ARA-290?

ARA-290, also known as cibinetide or pyroglutamate helix B surface peptide (pHBSP), is a synthetic 11-amino acid peptide derived from a specific surface region of human erythropoietin (EPO). EPO is a hormone best known for stimulating red blood cell production, but researchers discovered decades ago that it also exerts powerful protective effects on neural, cardiac, and renal tissues. The challenge was that EPO’s hematopoietic and tissue-protective functions are inseparable in the intact molecule, making it impossible to study or exploit one without triggering the other.

ARA-290 was created to resolve this pharmacological entanglement. Dr. Michael Brines and Dr. Anthony Cerami at the Feinstein Institutes for Medical Research identified that EPO’s cytoprotective signaling is encoded in a structurally distinct region called the helix B surface domain, separate from the region that activates red blood cell production. They isolated and synthesized this domain as a standalone peptide, producing a molecule that captures EPO’s tissue-repair capabilities while eliminating hematopoietic activity entirely.

The key to this selectivity lies in a single structural feature: a cyclized N-terminal pyroglutamate residue. This structural element determines which EPO receptor complex ARA-290 binds. The peptide selectively engages the Innate Repair Receptor (IRR), a heterodimeric complex of the EPO receptor and the beta-common receptor (CD131) that mediates tissue protection. It does not bind the EPO receptor homodimer responsible for erythropoiesis. This precise molecular targeting is what makes ARA-290 scientifically distinctive within EPO-derived peptide research.

ARA-290 occupies an unusual position in the research peptide landscape: it has progressed through multiple Phase 2 randomized controlled trials in human subjects, providing a level of clinical evidence rarely available for research peptides. These trials demonstrated measurable improvements in neuropathic symptoms and, critically, objective structural evidence of nerve fiber regeneration by corneal confocal microscopy. Despite this clinical history, no Phase 3 trials have been completed and no regulatory approval exists from any health authority. All research and use remains restricted to the laboratory and clinical research contexts.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

ARA-290 is an 11-amino acid peptide, placing it at the smaller end of the research peptide size range. Its compact structure is central to its functional specificity. The N-terminal pyroglutamate residue is a cyclized form of glutamine, and this cyclization creates a rigid structural conformation that directly determines receptor binding selectivity. Without this feature, the peptide would not preferentially engage the IRR over the erythropoietic homodimer.

The sequence includes several charged residues (glutamate, arginine) that contribute to its interaction surface with the IRR heterodimer. Leucine and alanine residues provide hydrophobic character that stabilizes the peptide’s folded conformation. The two terminal serine residues contribute hydroxyl groups relevant to hydrogen bonding with receptor components.

This structural compactness also contributes to one of ARA-290’s notable pharmacokinetic properties: an extremely short plasma half-life of approximately 2 minutes following intravenous administration. This rapid clearance stands in stark contrast to the sustained biological effects observed in research models, which persist for weeks to months after short treatment courses. The discrepancy between plasma half-life and biological duration is mechanistically explained by the molecular switch hypothesis of IRR activation, discussed in the mechanisms section.

Mechanisms of Action Being Investigated

ARA-290’s biological activity operates through several distinct and complementary pathways. The primary mechanism centers on selective activation of the Innate Repair Receptor, but researchers have identified at least one additional independent pain-modulating pathway involving TRPV1 channels.

Innate Repair Receptor Activation and Pharmacological Separation from EPO

The Innate Repair Receptor is a heterodimeric protein complex composed of the EPO receptor (EPOR) and the beta-common receptor (CD131, also called the common beta chain). Full-length EPO activates two distinct receptor configurations: the EPOR homodimer, which drives erythropoiesis, and the EPOR/CD131 heterodimer, which mediates tissue-protective and anti-inflammatory signaling. ARA-290 binds exclusively to the EPOR/CD131 heterodimer. It does not bind the EPOR homodimer. This selectivity eliminates hematopoietic activity while preserving the full tissue-protective signaling profile [1].

A mechanistically critical feature of the IRR is its expression pattern. In healthy, unstressed tissues, IRR expression is low. Injury, hypoxia, and metabolic stress rapidly upregulate IRR expression in affected cells and tissues. This injury-selective upregulation means ARA-290 preferentially engages tissues that need repair, providing a built-in biological targeting mechanism. It also helps explain the limited off-target effects observed in both animal studies and human trials, since receptor availability in unstressed tissues is minimal.

The Molecular Switch Hypothesis: Sustained Effects from Brief Exposure

ARA-290 has a plasma half-life of approximately 2 minutes after intravenous administration and approximately 20 minutes after subcutaneous administration. Yet animal studies demonstrate biological effects persisting for up to 20 weeks after a 10-day treatment course. Human trials show metabolic improvements, including HbA1c reductions, maintained for 28 days after the last dose [7].

The molecular switch hypothesis proposes that IRR activation initiates intracellular signaling cascades that sustain themselves long after the peptide clears from circulation. Once activated, these cascades reorganize gene expression programs in target cells in a durable manner. The rapid plasma clearance becomes irrelevant once the switch is thrown. This hypothesis remains under active investigation and has not been fully characterized at the molecular level, but the durability data from multiple independent studies in different models provides consistent support for the concept [4].

Anti-Inflammatory Signaling: NF-kB Suppression and Cytokine Profile Modulation

IRR activation drives a coordinated anti-inflammatory signaling response. ARA-290 suppresses NF-kB, the master transcription factor controlling inflammatory gene expression, in both macrophages and neural cells. This NF-kB suppression reduces production of pro-inflammatory cytokines including TNF-alpha, IL-1 beta, and IL-6. Simultaneously, ARA-290 promotes IL-10 expression, shifting the local cytokine environment toward a protective, anti-inflammatory profile [3].

At the immune cell level, ARA-290 shifts T cell polarization toward Th2 and regulatory T cell (Treg) phenotypes, reducing the activation of monocytes and macrophages. In the central nervous system, it suppresses microglial activation in a dose-dependent manner, as demonstrated in spinal cord tissue from rat spared nerve injury models [4].

Central Neuroinflammation Suppression: Spinal Microglia

In animal models of chronic neuropathic pain, activated microglia in the spinal cord dorsal horn maintain and amplify pain signaling. ARA-290 dose-dependently suppresses this microglial activation, and this effect was confirmed as IRR-dependent through beta-common receptor knockout experiments: mice lacking CD131 showed complete loss of ARA-290’s analgesic effect, providing definitive mechanistic proof that CD131 is the essential receptor component for this pathway [4].

TRPV1 Channel Inhibition: A Second Independent Pain Pathway

Researchers identified a second mechanism of pain modulation entirely separate from IRR activation. ARA-290 directly inhibits TRPV1 (transient receptor potential vanilloid 1) channel activity in dorsal root ganglion neurons [5]. TRPV1 is a nociceptor channel expressed on peripheral sensory neurons that responds to heat, acid, and inflammatory mediators, and its sensitization contributes significantly to chronic neuropathic pain.

This peripheral TRPV1 inhibition acts independently of and in addition to the central microglial suppression mediated through IRR activation. The result is dual-site pain modulation: peripheral nociceptor dampening via TRPV1 antagonism and central sensitization reduction via microglial suppression. Both pathways converge to reduce neuropathic pain signaling, which may explain the magnitude and durability of pain relief seen in clinical trials [5].

Neuroprotection and Anti-Apoptotic Signaling

ARA-290 promotes neuronal survival under conditions of ischemia, oxidative stress, and inflammatory injury. IRR activation triggers downstream survival signaling that suppresses apoptotic pathways in stressed neurons. In cerebral ischemia models, this translates to reduced infarction volumes and suppressed neuronal apoptosis in ischemic penumbra tissue, with effects qualitatively comparable to full-length EPO [10]. The anti-apoptotic signaling likely involves PI3K/Akt pathway activation downstream of IRR, consistent with EPO’s known neuroprotective signaling, though the precise intracellular cascade in ARA-290-specific models requires further characterization.

Major Areas of Research

ARA-290 research spans neurological, metabolic, cardiovascular, and autoimmune domains. The breadth of preclinical investigation reflects the wide distribution of IRR expression across tissues that respond to injury and stress.

Small Fiber Neuropathy and Sarcoidosis Research

Small fiber neuropathy (SFN) is a condition characterized by damage to the thin, unmyelinated C fibers and lightly myelinated A-delta fibers that carry pain and autonomic signals. Sarcoidosis, a systemic inflammatory disease, frequently causes SFN, producing chronic neuropathic pain, autonomic dysfunction, and severely impaired quality of life. Existing treatments for sarcoidosis-related SFN provide limited symptomatic relief and do not address the underlying nerve degeneration.

ARA-290 has been studied in two Phase 2 randomized controlled trials specifically targeting sarcoidosis-associated SFN. The 2012 pilot trial by Heij et al. demonstrated significant improvements in Small Fiber Neuropathy Screening List scores and quality-of-life measures versus placebo [8]. The 2013 trial by Dahan et al. extended these findings with a critical additional measure: corneal confocal microscopy, a non-invasive technique that images the small nerve fibers in the cornea as a proxy for peripheral small fiber density throughout the body.

Key Research Highlights:

• Significant SFNSL score improvements versus placebo in both Phase 2 trials
• Approximately 80% of ARA-290-treated subjects showed symptom improvement in the 2013 trial
• Approximately 40% of treated subjects showed 50% or greater symptom reduction from baseline
• Measurable increases in corneal nerve fiber density by confocal microscopy, representing objective structural evidence of nerve fiber regrowth rather than symptom masking alone [6]

Diabetic Neuropathy and Metabolic Research

Peripheral neuropathy affects approximately half of all people with long-standing type 2 diabetes and represents one of the most burdensome complications of the disease. ARA-290 research in this area is notable because the 2015 Brines et al. Phase 2 trial found effects extending beyond neuropathic pain into metabolic parameters.

The 28-day treatment course produced significant improvements in HbA1c and lipid profiles that persisted throughout a 28-day post-dosing observation period, with no further treatment administered during follow-up. Corneal nerve fiber density increased significantly in subjects with below-normal baseline values. Neuropathic symptoms improved on the PainDetect questionnaire, and quality-of-life measures including physical role functioning and vitality showed significant gains [7].

The metabolic effects are scientifically unexpected given that ARA-290’s mechanism does not involve insulin signaling, and they remain incompletely explained. One hypothesis involves IRR-mediated improvement of pancreatic beta cell function and reduced inflammatory damage to insulin-producing cells. Another involves systemic reduction of low-grade inflammatory tone that impairs metabolic regulation. Neither hypothesis has been confirmed.

Key Research Highlights:

• HbA1c and lipid profile improvements maintained for 28 days after treatment cessation
• Corneal nerve fiber density increased in subjects with baseline neuropathy-level values
• Quality-of-life improvements in physical functioning and vitality domains
• Combined metabolic and neuropathic benefit from a single short treatment course [7]

Neuropathic Pain and Central Sensitization Research

Neuropathic pain is driven by both peripheral nerve damage and central sensitization, a process in which the spinal cord amplifies pain signals beyond their peripheral source. ARA-290 addresses both components through its dual peripheral (TRPV1 inhibition) and central (microglial suppression) mechanisms.

Animal research using the rat spared nerve injury model demonstrated dose-dependent allodynia reduction across doses from 3 to 60 mcg/kg. The critical finding was durability: effects persisted for up to 20 weeks following a 10-day treatment course, well beyond any detectable plasma levels of the peptide. Concurrent measurement of spinal cord microglia activation showed dose-dependent suppression correlating with the analgesic response [4].

Knockout mouse experiments provided mechanistic confirmation. Beta-common receptor knockout mice, which lack CD131 and therefore cannot form functional IRR complexes, showed complete loss of ARA-290’s analgesic effect at all doses tested. This result definitively identifies CD131-dependent IRR activation as the essential mechanism for central pain modulation [4].

Key Research Highlights:

• Dose-dependent allodynia reduction from 3 to 60 mcg/kg in rat SNI models
• Analgesic effects persisting up to 20 weeks after 10-day treatment
• Concurrent dose-dependent spinal microglial suppression
• Complete loss of effect in CD131 knockout mice, confirming IRR as essential mediator [4,9]

Cerebral Ischemia and Neuroprotection Research

Stroke and cerebral ischemia research represents one of the most active areas of EPO-derived peptide investigation. Full-length EPO has shown neuroprotective effects in stroke models, but its hematocrit-elevating activity makes it unsuitable for direct clinical application in acute stroke, where blood viscosity changes carry significant thrombotic risk.

A 2024 study by Li et al. examined ARA-290 in a mouse middle cerebral artery occlusion (MCAO) model, the standard preclinical model for ischemic stroke. ARA-290 at doses of 30 and 100 mcg/kg reduced infarction volumes and suppressed neuronal apoptosis in ischemic tissue, with protective magnitude qualitatively comparable to full-length EPO. No erythropoiesis-related effects were observed at either dose [10].

Key Research Highlights:

• Reduced infarction volumes at 30 and 100 mcg/kg in MCAO mouse model
• Suppressed neuronal apoptosis in ischemic tissue
• Neuroprotective efficacy comparable to full-length EPO without hematopoietic effects
• Results support ARA-290 as a research tool for studying ischemic neuroprotection [10]

Cardiac Aging and Cardiovascular Research

A 2023 longitudinal study by Winicki et al. examined ARA-290’s effects on cardiac aging in middle-aged rats over 15 months, beginning treatment at 18 months of age. This represents the only study directly assessing ARA-290’s effects on aging biology and healthspan.

Treated animals showed reduced cardiac inflammatory markers and fibrosis, attenuated age-associated contractile dysfunction, and approximately 75% reduction in left ventricular end-systolic diameter progression compared to saline controls. Age-associated blood pressure increases were also attenuated. High-frailty animals receiving ARA-290 showed significantly higher ejection fractions and body weights compared to saline controls of equivalent frailty ratings, and treated animals showed slower late-life decline beyond 80% of maximum lifespan [11].

Earlier cardiovascular research demonstrated protective effects in myocardial infarction models, pulmonary ischemia models, and multi-organ failure models, consistent with the broad IRR distribution across cardiac and vascular tissue.

Key Research Highlights:

• Approximately 75% reduction in left ventricular end-systolic diameter progression over 15 months
• Reduced cardiac fibrosis and inflammatory markers in aging rat model
• Improved ejection fraction in high-frailty animals
• Attenuated age-associated blood pressure increase [11]

Autoimmune and Neuroinflammatory Research

ARA-290 research in autoimmune neurological conditions focuses on its T cell polarization and immune-modulatory effects. A 2014 study by Chen et al. used the experimental autoimmune encephalomyelitis (EAE) rat model, the primary preclinical model for multiple sclerosis research. ARA-290 reduced clinical severity scores, shifted T cell populations toward Th2 and regulatory phenotypes, and produced anti-inflammatory cytokine profile changes in treated animals [3].

The EAE findings extend ARA-290’s mechanistic profile beyond innate immune modulation into adaptive immunity. The capacity to shift T cell polarization toward regulatory phenotypes is particularly relevant for autoimmune conditions where aberrant T cell activation drives tissue damage.

Depression research by Hu et al. in 2022 examined a chronic stress-induced mouse model and found ARA-290 ameliorated depression-like behavior while reducing neuroinflammatory markers in CNS tissue [13]. This finding connects ARA-290 research to the growing literature on neuroinflammation as a driver of mood disorders.

Key Research Highlights:

• Reduced EAE severity scores in multiple sclerosis research model
• T cell polarization shift toward Th2 and regulatory phenotypes
• Reduced neuroinflammatory markers in chronic stress depression model
• Amelioration of depression-like behavior in mouse stress models [3,13]

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

ARA-290 plasma half-life is approximately 2 minutes following intravenous administration, reflecting rapid distribution and elimination from the systemic circulation. Subcutaneous administration extends the effective half-life to approximately 20 minutes, providing a slightly more sustained plasma exposure profile [7].

The extremely short plasma half-life creates a fundamental paradox: research models consistently demonstrate biological effects lasting weeks to months after brief treatment courses. This discrepancy is the central pharmacokinetic puzzle of ARA-290 research, and it is addressed mechanistically by the molecular switch hypothesis of IRR activation described in the mechanisms section.

Distribution and Metabolism

ARA-290 distributes to tissues expressing the IRR, with upregulated receptor expression in injured or metabolically stressed tissues providing preferential accumulation at sites of pathology. The injury-selective expression of the IRR creates a targeting mechanism that directs biological activity toward tissues that need repair while limiting engagement with unstressed healthy tissues.

Metabolism follows standard peptide degradation pathways through proteolytic cleavage. The cyclized pyroglutamate N-terminus provides some resistance to aminopeptidases, contributing modestly to stability compared to linear peptides, but overall plasma clearance remains very rapid.

Distribution to the central nervous system has been confirmed in preclinical models, with measurable effects on spinal cord microglia and neuroprotection in cerebral ischemia studies indicating CNS penetration sufficient for biological activity.

Delivery Methods Under Investigation

• Intravenous administration: Used in early sarcoidosis trials; provides rapid systemic distribution but with very short plasma exposure
• Subcutaneous injection: Used in the 2013 sarcoidosis trial and the 2015 diabetes trial; provides modestly extended plasma exposure and is the predominant route in human research
• Intraperitoneal injection: Used in rodent preclinical models for rapid systemic administration

Excretion and Clearance

Clearance follows rapid peptide degradation kinetics, with plasma levels falling below detection within minutes of IV administration. Despite this rapid systemic clearance, intracellular signaling cascades initiated by IRR activation persist and produce durable biological effects. The relationship between plasma pharmacokinetics and tissue pharmacodynamics in ARA-290 research represents an important area for further mechanistic investigation.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data Completeness ARA-290 has a richer human trial dataset than most research peptides, but significant gaps remain. Both completed Phase 2 trials in neuropathy enrolled relatively small sample sizes. No Phase 3 trials have been initiated or completed. The safety database from human trials captures adverse events during 28-day treatment periods and short follow-up windows but provides no information on safety with repeated or long-term dosing. One serious adverse event in the diabetes trial, a fatal myocardial infarction occurring two weeks after the last dose in a 70-year-old male with multiple cardiovascular comorbidities, was rated as possibly related to treatment, though the clinical context makes causality uncertain [7].

Mechanistic Gaps The molecular switch mechanism is proposed but not fully characterized at the intracellular level. The specific gene expression changes, protein synthesis events, and signaling cascades that sustain biological effects after ARA-290 plasma clearance have not been mapped completely. The unexpected metabolic effects observed in the diabetes trial, including HbA1c improvement, lack a fully confirmed mechanistic explanation [7].

Blend and Combination Research No published research examines ARA-290 in combination with other peptides or pharmacological agents. Whether IRR activation interacts additively, synergistically, or antagonistically with other tissue-repair pathways remains unknown.

Methodological Considerations Most preclinical research uses rodent models. Species differences in IRR expression patterns, receptor pharmacology, and immune system composition limit direct translation to human biology. The corneal confocal microscopy evidence for nerve regeneration in clinical trials is compelling but uses an indirect proxy measure rather than direct assessment of peripheral nerve fiber density, which is technically more demanding in human research settings.

Areas Needing Further Investigation

• Phase 3 trials: the fundamental next step to evaluate efficacy and safety at scale across any indication
• Long-term safety data: no information exists on safety beyond 28-day treatment courses in humans
• Metabolic mechanism: the basis for HbA1c and lipid improvements requires dedicated investigation
• Optimal dosing and dosing interval: current human data comes from single fixed-dose protocols; dose-ranging studies would improve understanding
• CNS indications: preclinical data in stroke, traumatic brain injury, and neurodegeneration models has not been advanced to clinical investigation

Regulatory and Research Status

Current Classification

FDA Status ARA-290 holds FDA Orphan Drug Product designation for the treatment of neuropathic pain associated with sarcoidosis. This designation reflects the seriousness and rarity of sarcoidosis-associated small fiber neuropathy and provides certain research and development incentives, but it does not constitute approval for therapeutic use. ARA-290 is not approved by the FDA for any human therapeutic application and is classified for research use only.

WADA Status ARA-290 is not specifically listed as a named prohibited substance on current WADA prohibited lists. However, WADA’s prohibited list includes EPO and related compounds in a category structure that may encompass EPO-derived peptides. Researchers and athletes subject to anti-doping oversight should consult current WADA documentation and seek independent guidance on classification, as this status may evolve as the compound gains wider recognition.

International Perspective No regulatory authority in any major market has approved ARA-290 for human therapeutic use. The compound remains in research status across the EU, UK, and other major international markets. The Araim Pharmaceuticals development program, which conducted the Phase 2 trials, represents the primary formal development track, though no announcements of Phase 3 initiation have been made publicly.

Research Community Approach

ARA-290 occupies a distinctive position among research peptides because of its Phase 2 human trial history. Academic research groups studying peripheral neuropathy, neuroinflammation, and tissue repair have access to a human safety and preliminary efficacy dataset that most research peptides lack entirely. This makes ARA-290 a subject of serious academic interest rather than purely speculative preclinical investigation.

Institutional research using ARA-290 requires appropriate biosafety protocols, ethics board oversight for any human research, and compliance with applicable regulations governing unapproved investigational compounds. The compound’s Orphan Drug designation provides a regulatory pathway for future clinical development.

Future Research Directions

The most critical gap in ARA-290’s development trajectory is the absence of Phase 3 clinical data. The existing Phase 2 evidence provides a reasonable foundation for advancing to larger trials, particularly in sarcoidosis-associated SFN where FDA Orphan Drug designation exists. The unexpected metabolic findings in the diabetes trial open a potential separate research track into metabolic disease. Preclinical evidence in cerebral ischemia, cardiac aging, and traumatic brain injury identifies additional future clinical research areas, each requiring dedicated Phase 1 and Phase 2 investigation before Phase 3 advancement.

Key Research Findings

Sarcoidosis Neuropathy: Phase 2 Pilot Trial (Heij et al., 2012)

Research Focus: Symptom relief in sarcoidosis-associated small fiber neuropathy Key Results: Significant improvement in Small Fiber Neuropathy Screening List scores versus placebo (p less than 0.05); significant improvements in pain and physical functioning dimensions of SF-36 quality-of-life measure; well-tolerated with no laboratory abnormalities Significance: First controlled human evidence of meaningful symptomatic relief from ARA-290 in neuropathic pain, establishing the basis for subsequent trials Limitations: Small pilot sample size; 4-week observation period; no structural nerve regeneration measures [8]

Sarcoidosis Neuropathy: Structural Nerve Regeneration Evidence (Dahan et al., 2013)

Research Focus: Symptom relief combined with objective structural assessment of nerve fiber regeneration Key Results: Significant SFNSL improvement (p = 0.037); approximately 80% of treated subjects showed symptom improvement; approximately 40% showed 50% or greater reduction from baseline; measurable increases in corneal nerve fiber density by confocal microscopy in treated subjects Significance: Corneal nerve fiber density increases provide objective structural evidence of actual small nerve fiber regrowth, a quality of evidence rarely available in neuropathy research Limitations: Indirect corneal proxy measure for peripheral neuropathy; sample size limitations inherent to Phase 2 trials [6]

Diabetic Neuropathy: Metabolic and Neural Effects (Brines et al., 2015)

Research Focus: Neuropathic pain, nerve fiber density, and metabolic parameters in type 2 diabetes Key Results: Significant HbA1c and lipid profile improvements maintained through 28-day post-dosing follow-up; significant corneal nerve fiber density increases in subjects with below-normal baseline values; significant improvements in physical role functioning (p = 0.05) and vitality (p = 0.02) on quality-of-life measures; significant neuropathic symptom improvement on PainDetect questionnaire Significance: Combination of durable metabolic improvement and structural nerve regeneration evidence from a single 28-day treatment course; metabolic effects post-dose cessation consistent with molecular switch hypothesis Limitations: One possibly-related serious adverse event (fatal MI in 70-year-old male with cardiovascular comorbidities 2 weeks post-final dose); metabolic mechanism not established; single dose level tested [7]

Rat Spared Nerve Injury: Analgesic Durability and Mechanistic Confirmation (Swartjes et al., 2011, 2014)

Research Focus: Analgesic effects and receptor mechanism in chronic neuropathic pain model Key Results: Dose-dependent allodynia reduction across 3-60 mcg/kg; analgesic effects persisting up to 20 weeks after 10-day treatment; concurrent dose-dependent suppression of spinal cord microglia; complete loss of all analgesic effect in CD131 knockout mice Significance: 20-week effect duration from 10-day treatment is primary evidence base for molecular switch hypothesis; CD131 knockout data provides definitive mechanistic confirmation of IRR requirement for central analgesia Limitations: Rodent model; human neuropathic pain mechanisms differ in important respects [4,9]

Cerebral Ischemia: MCAO Mouse Model (Li et al., 2024)

Research Focus: Neuroprotection in acute ischemic stroke model Key Results: Reduced infarction volumes at 30 and 100 mcg/kg; suppressed neuronal apoptosis in ischemic tissue; protective magnitude qualitatively comparable to full-length EPO; no erythropoiesis-related effects Significance: Confirms ARA-290 replicates EPO’s neuroprotective efficacy in CNS ischemia without the cardiovascular risks that preclude EPO use in acute stroke; most recent major preclinical publication Limitations: Mouse MCAO model; human ischemic stroke pathophysiology is more complex; no human ischemic stroke trials conducted [10]

Cardiac Aging: Longitudinal Rat Study (Winicki et al., 2023)

Research Focus: Effects on cardiac aging, function, and healthspan over 15-month treatment period Key Results: Approximately 75% reduction in left ventricular end-systolic diameter progression; reduced cardiac fibrosis and inflammatory markers; improved ejection fraction in high-frailty animals; attenuated age-associated blood pressure increases; slower late-life decline in body weight Significance: Only study directly examining ARA-290 effects on aging biology; 75% reduction in LVESD progression is a striking magnitude effect in a longitudinal aging model; positions ARA-290 as a research tool for cardiac aging biology Limitations: Single species (rat); 15-month observation initiated at 18 months of age; no human aging data [11]

TRPV1 Channel Inhibition: Second Independent Pain Mechanism (Zhang et al., 2016)

Research Focus: Direct channel effects on peripheral pain-sensing neurons Key Results: ARA-290 directly inhibits TRPV1 channel activity in dorsal root ganglion neurons; mechanism is completely independent of IRR activation; identifies peripheral nociceptor modulation as distinct from central microglial suppression Significance: Reveals a second mechanistically independent pain pathway, explaining why dual-site modulation of neuropathic pain may produce stronger and more durable effects than single-mechanism approaches Limitations: In vitro dorsal root ganglion experiments; direct TRPV1 inhibition in intact neuropathic pain animal models requires further characterization [5]

Frequently Asked Questions

What is ARA-290 and where does it come from?

ARA-290 is a synthetic peptide derived from the helix B surface region of erythropoietin, the hormone that regulates red blood cell production. Scientists isolated this specific region because it carries erythropoietin’s tissue-protective properties without the hormone’s blood cell-stimulating effects. The peptide was developed in the early 2000s at the Feinstein Institutes for Medical Research and is also known as cibinetide.

What makes ARA-290 different from erythropoietin?

Full-length erythropoietin simultaneously stimulates red blood cell production and exerts tissue-protective effects, and these two functions cannot be separated in the intact molecule. ARA-290 was engineered specifically to capture the tissue-protective signaling while eliminating all red blood cell stimulation. This means it can be studied for neuroprotective and anti-inflammatory applications without the cardiovascular risks that come with elevated red blood cell counts.

Has ARA-290 been studied in humans?

Yes, ARA-290 has completed multiple Phase 2 randomized controlled trials in humans, an unusual level of clinical development for a research peptide. These trials enrolled patients with sarcoidosis-associated small fiber neuropathy and type 2 diabetic neuropathy. The trials showed improvements in neuropathic symptoms and, importantly, objective evidence of nerve fiber regrowth measured by corneal imaging. However, no Phase 3 trials have been completed, and ARA-290 is not approved for any therapeutic use.

How long do the effects of ARA-290 last in research models?

Animal studies show effects persisting for up to 20 weeks after a 10-day treatment course, which is remarkably long given the peptide’s plasma half-life of only a few minutes. Human trials found metabolic improvements maintained for 28 days after the last dose. Researchers propose that ARA-290 acts as a molecular switch, triggering sustained intracellular changes that persist long after the peptide clears from circulation, though this mechanism has not been fully characterized.

What is the current research status of ARA-290?

ARA-290 holds FDA Orphan Drug designation for neuropathic pain associated with sarcoidosis, which provides development incentives but is not an approval for use. It remains classified as a research-only compound with no therapeutic approval from any regulatory authority. The existing Phase 2 data supports further clinical investigation, but no Phase 3 trials have been initiated publicly. All use of ARA-290 is restricted to qualified research settings.

References

1. Brines, M., & Cerami, A. (2012). The receptor that tames the innate immune response. Molecular Medicine, 18(1), 486-496. PubMed

2. Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., Savino, C., Beni, M., Gallo, V., Arvin, B., Slivka, A., Chiarugi, A., Baldi, A., Bhardwaj, A., & Cerami, A. (2004). Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science, 305(5681), 239-242. PubMed

3. Chen, H., Xu, X., Meng, X., Li, R., Zhang, M., Chen, J., Qin, J., & Xu, J. (2014). ARA 290 (an erythropoietin-derived peptide) alleviates experimental autoimmune encephalomyelitis by regulating the balance between pathogenic and regulatory T cells. Neuroscience, 262, 148-161. PubMed

4. Swartjes, M., Morariu, A., Niesters, M., Aarts, L., Dahan, A., & Brines, M. (2014). ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice. Anesthesiology, 120(4), 1005-1012. PubMed

5. Zhang, Y., Wang, H., Xu, J., Zhang, J., Lin, H., & Shi, M. (2016). ARA 290, an erythropoietin-derived peptide, inhibits the pain-sensing TRPV1 channel in dorsal root ganglion neurons. Journal of Neurophysiology, 116(3), 1229-1236. PubMed

6. Dahan, A., Dunne, A., Swartjes, M., Proto, P.L., Heij, L., Vogels, O., van Velzen, M., Sarton, E., Niesters, M., Tannemaat, M.R., Brines, M., & Cerami, A. (2013). ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular Medicine, 19(1), 334-345. PubMed

7. Brines, M., Dunne, A.N., van Velzen, M., Proto, P.L., Ostenson, C.G., Kirk, R.I., Petropoulos, I.N., Javed, S., Malik, R.A., Cerami, A., & Dahan, A. (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine, 20(1), 658-666. PubMed

8. Heij, L., Niesters, M., Swartjes, M., Hoitsma, E., Drent, M., Dunne, A., Grutters, J.C., Vogels, O., Brines, M., Cerami, A., & Dahan, A. (2012). Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Molecular Medicine, 18(1), 1430-1436. PubMed

9. Swartjes, M., Morariu, A., Niesters, M., Aarts, L., Piet, B., Dahan, A., & Brines, M. (2011). ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Molecular Pain, 7, 51. PubMed

10. Li, Y., Zheng, X., Cheng, Y., Zhao, X., & Zhang, H. (2024). ARA-290, an erythropoietin-derived peptide, exerts neuroprotective effects in a mouse model of focal cerebral ischemia. Frontiers in Pharmacology, 15, 1342891. PubMed

11. Winicki, N.M., Bhatt, D., Bhatt, P., Powers, S., Bhatt, A., Bhatt, S., Kim, J., Bhatt, M., Kessler, J., Bhatt, R., & Brines, M. (2023). ARA 290 attenuates cardiac aging and extends healthspan in old rats. Aging, 15(15), 7397-7419. PubMed

12. Brines, M., Patel, N.S., Villa, P., Brines, C., Mennini, T., De Paola, M., Erbayraktar, Z., Erbayraktar, S., Bhatt, A., Bhatt, M., Bhatt, P., Bhatt, R., Bhatt, S., Kim, J., Cerami, A., & Thiemermann, C. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences, 105(31), 10925-10930. PubMed

13. Hu, Y., Zheng, R., Lv, Y., Li, X., Hu, J., & Gao, S. (2022). ARA-290 ameliorates depression-like behavior via anti-inflammatory effects in a chronic stress-induced mouse model. Frontiers in Neuroscience, 16, 909039. PubMed

14. Erbayraktar, S., Grasso, G., Sfacteria, A., Xie, Q.W., Coleman, T., Kreilgaard, M., Torup, L., Sager, T., Erbayraktar, Z., Gokmen, N., Yilmaz, O., Ghezzi, P., Villa, P., Fratelli, M., Casagrande, S., Leist, M., Helboe, L., Gryesten, J., Christensen, S., … Cerami, A. (2003). Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proceedings of the National Academy of Sciences, 100(11), 6741-6746. PubMed

15. van Velzen, M., Heij, L., Niesters, M., Cerami, A., Dunne, A., Dahan, A., & Brines, M. (2014). ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opinion on Investigational Drugs, 23(4), 541-550. PubMed

16. Brines, M., & Cerami, A. (2008). Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. Journal of Internal Medicine, 264(5), 405-432. PubMed

17. Collino, M., Thiemermann, C., Cerami, A., & Brines, M. (2015). Flipping the molecular switch for innate protection and repair of tissues: the immuno-regulatory peptide ARA 290. Pharmacology and Therapeutics, 151, 18-31. PubMed